
Viridian Therapeutics (VRDN) Stock Forecast & Price Target
Viridian Therapeutics (VRDN) Analyst Ratings
Bulls say
Viridian Therapeutics Inc. demonstrates a promising outlook due to its product candidate Veligrotug, which has shown potential to match and even surpass the benefits of existing therapies for thyroid eye disease (TED), specifically in proptosis and diplopia reduction. The introduction of the subcutaneous formulation, VRDN-003, is expected to strengthen the company’s market position by improving treatment accessibility and patient quality of life, thus enhancing market share. Moreover, the company’s second-mover advantage allows it to address the shortcomings of current therapies, positioning Viridian for significant advancements in autoimmune treatment and future commercial success.
Bears say
The analysis indicates a negative outlook for Viridian Therapeutics due to several fundamental concerns, including potential vulnerabilities in intellectual property protection that could jeopardize its competitive positioning in the market. Additionally, risks associated with the manufacturing process and the pressures of an accelerated Biologics License Application (BLA) timeline raise doubts about management's execution capabilities, which could negatively impact future commercialization efforts. Furthermore, the company faces substantial competition from well-capitalized rivals with established products, which may hinder Viridian's market share and pricing power, compounded by the high treatment burden associated with existing therapies like Tepezza, potentially limiting patient adoption.
This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viridian Therapeutics (VRDN) Analyst Forecast & Price Prediction
Start investing in Viridian Therapeutics (VRDN)
Order type
Buy in
Order amount
Est. shares
0 shares